Bioventus Inc. (BVS): Price and Financial Metrics Recent IPO
GET POWR RATINGS... FREE!
BVS Stock Price Chart Interactive Chart >
BVS Price/Volume Stats
|Current price||$17.25||52-week high||$19.94|
|Prev. close||$17.15||52-week low||$10.74|
|Day high||$17.64||Avg. volume||186,962|
|50-day MA||$17.24||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||980.23M|
Bioventus Inc. (BVS) Company Bio
Bioventus Inc. focuses on operating as a holding company for Bioventus LLC that operates as a medical device company. It develops and commercializes clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is based in Durham, North Carolina.
BVS Latest News Stream
|Loading, please wait...|
BVS Latest Social Stream
View Full BVS Social Stream
Latest BVS News From Around the Web
Below are the latest news stories about Bioventus Inc that investors may wish to consider to help them evaluate BVS as an investment opportunity.
Bioventus® Management to Present at Canaccord Genuity Growth Conference and Morgan Stanley Virtual Global Healthcare Conference
DURHAM, N.C., July 27, 2021 (GLOBE NEWSWIRE) -- Senior management of Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12 at 3:30 p.m. ET and the Morgan Stanley Virtual Global Healthcare Conference on Friday, September 10 at 9:30 a.m. ET. Both events are virtual conferences. Presentation materials for the events will be available in the investor re
Mary Kay Ladone Bioventus Board Member Bioventus Appoints Mary Kay Ladone to its Board of Directors DURHAM, N.C., July 14, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has announced the appointment of Mary Kay Ladone to the Company’s Board of Directors, effective July 15, 2021. In addition, she was appointed to the Board’s Audit and Risk Committee (the “Audit Committee”) and Compensation Committee. Ladone
OSTEOAMP SELECT Flowable from Bioventus A demonstration of how OSTEOAMP SELECT Flowable can be easily delivered in minimally invasive settings. DURHAM, N.C., July 13, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, is launching OSTEOAMP SELECT Flowable, a flowable allograft bone graft substitute solution developed for a variety of patient procedures including lumbar spine fusion, cervical spine fusion and fo
Bioventus' (NASDAQ:BVS) stock is up by a considerable 15% over the past three months. Since the market usually pay for...
The Dow Jones slumped as the Nasdaq gained. Apple stock closed in on a new buy point. AMC stock surged, while GameStop stock also gained.
BVS Price Returns